Delparantag

Drug Profile

Delparantag

Alternative Names: Delparantag pentahydrochloride; Heptagonist - PolyMedix; PMX-60056

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PolyMedix
  • Class Benzamides; Coagulants; Small molecules
  • Mechanism of Action Heparin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Blood coagulation disorders

Most Recent Events

  • 07 Jun 2017 Cellceutix is now called Innovation Pharmaceuticals
  • 04 Sep 2013 Cellceutix acquires delparantag from PolyMedix
  • 01 Apr 2013 PolyMedix files for Chapter 7 bankruptcy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top